Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.40 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 5/20 | 0.35 |
| ▸ | MMP3 | P08254 | 5/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | Q9HBH1 | 1/20 | 0.35 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28248774 | 0.93 | GPR84 (0.46) | GPR84HSPD1BLMHSPE1 | |
| SCHEMBL17848847 | 0.88 | TDP1 (0.36) | GPR84HSPD1BLMHSPE1CA2 | |
| SCHEMBL24204829 | 0.81 | HSPD1 (0.38) | GPR84HSPD1BLMHSPE1CA2 | |
| SCHEMBL20169630 | 0.81 | CA2 (0.39) | GPR84HSPD1BLMHSPE1CA2 | |
| SCHEMBL31109151 | 0.80 | HSPD1 (0.41) | GPR84HSPD1BLMHSPE1CA2 | |
| SCHEMBL3884302 | 0.79 | TDP1 (0.39) | GPR84HSPD1BLMHSPE1 | |
| SCHEMBL29149143 | 0.79 | CA2 (0.38) | GPR84HSPD1BLMHSPE1CA2 | |
| SCHEMBL28047044 | 0.79 | GPR84 (0.43) | GPR84HSPD1BLMHSPE1CA2 | |
| SCHEMBL3419467 | 0.78 | TDP1 (0.34) | — | |
| SCHEMBL24667111 | 0.78 | GPR84 (0.46) | GPR84HSPD1BLMHSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529394-B2 | Polypeptide conjugates and methods of uses | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20220133856-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
| CN-105085728-B | A kind of method and its catalyst preparing catalyst component for olefin | 中国石油化工股份有限公司 | 2018-10-16 | — | — | CN | disclosed |
| CN-108570119-A | A kind of ingredient of solid catalyst containing naphthylenediamine class compound, catalyst and its application | 北京利和知信科技有限公司 | 2018-09-25 | — | — | CN | disclosed |
| CN-108570120-A | Ingredient of solid catalyst and catalyst containing o-phenylenediamine class compound and its application | 北京利和知信科技有限公司 | 2018-09-25 | — | — | CN | disclosed |
| CN-108517022-A | For the ingredient of solid catalyst and its catalyst of olefinic polymerization and application | 北京利和知信科技有限公司 | 2018-09-11 | — | — | CN | disclosed |
| CN-108219295-A | Polypropene composition, polypropylene film-making material and its manufacturing method and secondary forming body | 富比食品包装有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-108117617-A | A kind of ingredient of solid catalyst and catalyst for olefinic polymerization | 任丘市利和科技发展有限公司 | 2018-06-05 | — | — | CN | disclosed |
| CN-103923238-B | Catalytic component and catalyst for olefinic polymerization | 北京利和知信科技有限公司 | 2018-03-02 | — | — | CN | disclosed |
| CN-104109212-B | Solid catalyst component for olefine polymerization and catalyst | 北京利和知信科技有限公司 | 2017-11-07 | — | — | CN | disclosed |
| CN-104479055-B | A kind of dialkoxy-magnesium support type ingredient of solid catalyst and catalyst | 任丘市利和科技发展有限公司 | 2017-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529394-B2 | Polypeptide conjugates and methods of uses | GLP1R, GIPR, IAPP | GPR84 120/4885HSPD1 2552/4885BLM 2317/4885 |
| US-20220133856-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | GLP1R, GIPR, IAPP | GPR84 120/4885HSPD1 2552/4885BLM 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.